Back to top
more

PDS Biotechnology (PDSB)

(Real Time Quote from BATS)

$3.21 USD

3.21
198,747

+0.01 (0.31%)

Updated Apr 24, 2024 11:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PDSB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

PDS Biotechnology Corporation [PDSB]

Reports for Purchase

Showing records 1 - 20 ( 61 total )

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 1

11/14/2023

Company Report

Pages: 8

3Q23 Results; Progress Continues Across the Pipeline; VERSATILE-003 Initiation Expected in 1Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 2

11/09/2023

Company Report

Pages: 8

NCI Triplet Study Delivers Real Nice Survival Update; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 3

10/23/2023

Company Report

Pages: 8

Biomarker Analysis Highlights PDS0101''s Immune Activating Properties in HNSCC

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 4

10/11/2023

Company Report

Pages: 8

Initial Phase 1/2 Data Showcase PDS0301''s MoA and Safety Profile in mPC

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 5

10/03/2023

Company Report

Pages: 8

Strong Phase 2 Update and KOL Event Highlight Promising Road For PDS0101

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 6

10/02/2023

Company Report

Pages: 8

Versamune Demonstrates Broad Applicability From Oncology to Infectious Disease

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 7

09/27/2023

Company Report

Pages: 12

PDS0101 Could be Just What the Doctor Ordered For Investors and the Cancer Vaccine Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 8

09/20/2023

Daily Note

Pages: 8

Gearing Up Against the Flu; PDS0202 Neutralizes Multiple Influenza Strains in Preclinical Studies

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 9

08/14/2023

Company Report

Pages: 8

2Q23 Results; Going Pivotal Soon; VERSATILE-003 Initiation Expected in 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 10

06/14/2023

Daily Note

Pages: 6

PDS0101 Continues to Show Clinical Benefit in HNSCC as VERSATILE-002 Meets Key Clinical Efficacy Metric

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 11

06/06/2023

Company Report

Pages: 8

PDS0101 Continues to Impress at ASCO; Phase 3 Start Expected in 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 12

05/26/2023

Company Report

Pages: 6

VERSATILE-002 Survival Outcomes Shine as Study Matures; Full Presentation at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 13

05/15/2023

Company Report

Pages: 6

1Q23 Results; Immunotherapy Pipeline Advances; Updated VERSATILE-002 Data at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 14

04/24/2023

Company Report

Pages: 9

KOLs Highlight Differentiated IL-12 Approach and PDS0301

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 15

03/30/2023

Daily Note

Pages: 6

PDS0101 Ready to Take Next Step; VERSATILE-003 Phase 3 Registrational Study Poised to Begin 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 16

03/28/2023

Company Report

Pages: 8

2022 Results; PDS0101 Clinical Development Forges Ahead

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 17

02/27/2023

Daily Note

Pages: 6

Positive FDA Meeting Provides Next Layer of Visibility for PDS0101; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 18

01/03/2023

Company Report

Pages: 7

Pipeline Toolbox Expands; PDS0301 Joins the Pipeline; Target Increased to $21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 19

12/28/2022

Company Report

Pages: 7

PDS0101 Expanded Interim Data Continue to Support Durability of Triple Combo Therapy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: PDS Biotechnology Corporation

Industry: Medical - Biomedical and Genetics

Record: 20

12/15/2022

Daily Note

Pages: 5

First Stage of CKI Refractory Cohort in VERSATILE-002 Completes Enrollment

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party